Syndax Pharmaceuticals, Inc. News Releases http://ir.syndax.com/ Syndax Pharmaceuticals, Inc. News Releases en Syndax to Present at the JMP Securities Life Sciences Conference http://ir.syndax.com/news-releases/news-release-details/syndax-present-jmp-securities-life-sciences-conference WALTHAM, Mass. , June 13, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Thu, 13 Jun 2019 07:00:00 -0400 Syndax Pharmaceuticals, Inc. News Releases 9301 Syndax to Present at the UBS Global Healthcare Conference http://ir.syndax.com/news-releases/news-release-details/syndax-present-ubs-global-healthcare-conference WALTHAM, Mass. , May 14, 2019 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Tue, 14 May 2019 07:00:00 -0400 Syndax Pharmaceuticals, Inc. News Releases 9246 Syndax Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Clinical and Business Update http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-first-quarter-2019-financial - E2112 trial passes fourth interim analysis for OS; trial to continue, with next preplanned analysis expected in 4Q19 - - IND filing for targeted menin inhibitor SNDX-5613 on track for 2Q19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. Mon, 06 May 2019 16:05:00 -0400 Syndax Pharmaceuticals, Inc. News Releases 9216 Syndax to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 6, 2019 http://ir.syndax.com/news-releases/news-release-details/syndax-announce-first-quarter-2019-financial-results-and-host WALTHAM, Mass. , April 29, 2019 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2019 financial Mon, 29 Apr 2019 07:00:00 -0400 Syndax Pharmaceuticals, Inc. News Releases 9201 Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-presents-updated-phase-2-data-encore-601 - 19% objective response rate and 36% clinical benefit rate, with 13-month median duration of response in melanoma patients whose disease progressed on or after anti-PD-1 therapy - - Gene expression analyses provide mechanistic insight for enhanced clinical benefit observed in biomarker-defined Mon, 01 Apr 2019 10:33:00 -0400 Syndax Pharmaceuticals, Inc. News Releases 9186 Syndax Announces $26.2 Million Offering of Common Stock and Warrants http://ir.syndax.com/news-releases/news-release-details/syndax-announces-262-million-offering-common-stock-and-warrants WALTHAM, Mass. , March 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it has entered into an agreement with Biotechnology Value Wed, 27 Mar 2019 07:00:00 -0400 Syndax Pharmaceuticals, Inc. News Releases 9161 Syndax Pharmaceuticals Reports Fourth Quarter 2018 Financial Results and Provides Clinical and Business Update http://ir.syndax.com/news-releases/news-release-details/syndax-pharmaceuticals-reports-fourth-quarter-2018-financial - Next interim OS assessment for Phase 3 E2112 trial in HR+, HER2- metastatic breast cancer expected in 2Q19 - - IND filing for targeted therapy SNDX-5613, the Company's Menin inhibitor, expected in 2Q19 - - Company to host conference call today at 4:30 p.m. ET - WALTHAM, Mass. Thu, 07 Mar 2019 16:05:00 -0500 Syndax Pharmaceuticals, Inc. News Releases 9121 Syndax to Present at the Cowen 39th Annual Health Care Conference http://ir.syndax.com/news-releases/news-release-details/syndax-present-cowen-39th-annual-health-care-conference WALTHAM, Mass. , March 6, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Wed, 06 Mar 2019 07:00:00 -0500 Syndax Pharmaceuticals, Inc. News Releases 9116 Syndax to Announce Fourth Quarter and Year-end 2018 Financial Results and Host Conference Call and Webcast on March 7, 2019 http://ir.syndax.com/news-releases/news-release-details/syndax-announce-fourth-quarter-and-year-end-2018-financial WALTHAM, Mass. , Feb. 28, 2019 /PRNewswire/ --  Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its fourth quarter 2018 financial Thu, 28 Feb 2019 07:00:00 -0500 Syndax Pharmaceuticals, Inc. News Releases 9106 Syndax Announces Clinical Data from its Entinostat Immuno-oncology Program Selected for Two Oral Presentations at the American Association for Cancer Research Annual Meeting 2019 http://ir.syndax.com/news-releases/news-release-details/syndax-announces-clinical-data-its-entinostat-immuno-oncology WALTHAM, Mass. , Feb. 27, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced two oral presentations at the upcoming American Association Wed, 27 Feb 2019 16:47:00 -0500 Syndax Pharmaceuticals, Inc. News Releases 9101